Network toxicological insights into DEHP exposure and thyroid cancer development and progression

Article type: Research Article

Keywords: DEHP, network toxicological, thyroid cancer, TCGA, GEO

Authors: Yuhang Zhang, Qiang Wang

License: Copyright © 2025 Zhang and Wang. CC BY 4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Article links: DOI: 10.3389/fonc.2025.1617202  |  PubMed: 40900788  |  PMC: PMC12399584

Relevance: Relevant: mentioned in keywords or abstract

Full text: PDF (2.4 MB)

Introduction

There are numerous endocrine disruptors in the environment, including bisphenol A and phthalates, which have garnered significant attention in current research. These compounds are predominantly utilized in the manufacturing of plastics and cosmetics (ref. 1), as well as in food packaging and building materials (ref. 2). Notably, di-2-ethylhexyl phthalate (DEHP), a primary phthalate, is frequently detected in both environmental samples and human tissues (ref. 3) and is classified as potentially carcinogenic to humans (ref. 2).

The incidence of Thyroid Cancer (TC) is rising annually, with the majority of cases originating from follicular epithelial cells. These include papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). A study has demonstrated a significant association between exposure to bisphenol A (BPA) and di(2-ethylhexyl) phthalate (DEHP) and the risk of differentiated thyroid cancer (DTC) in patients with thyroid nodules (ref. 4). Additionally, experiments conducted on rats have shown that DEHP enhances the carcinogenic effects of BPA on the thyroid gland (ref. 5).

Recently, a growing body of evidence suggests that DEHP disrupts the function of the hypothalamic-pituitary-thyroid (HPT) axis (ref. 6, ref. 7). As a widely used plasticizer, DEHP can bioaccumulate through the food chain, leading to abnormal thyroid hormone (T3/T4) levels and oxidative stress (ref. 8). Studies have indicated that DEHP can induce thyroid hyperplasia via the arachidonic acid pathway, offering new insights into the potential link between DEHP exposure and thyroid cancer (ref. 9). Moreover, human urine tests have revealed a correlation between phthalate exposure and the incidence of papillary thyroid carcinoma (PTC), although further validation is required (ref. 10).

Most cases of highly differentiated thyroid cancer are asymptomatic and are typically detected during routine physical examinations or incidentally through diagnostic imaging. Consequently, timely targeted therapy is critical for improving patient outcomes (ref. 11). Despite growing evidence, the precise molecular networks and key driver genes linking DEHP exposure to thyroid cancer progression at a systems level remain incompletely understood. To address this knowledge gap, systems biology approaches, which integrate multi-omics data to dissect complex molecular interactions and identify core regulatory networks, have emerged as a powerful tool – their ability to capture the overall dynamics of biological systems aligns with the need to reveal the intricate links between environmental exposure (DEHP) and cancer progression. This study aims to elucidate the molecular network of thyroid cancer induced by DEHP and explore its potential association with clinical therapeutic targets. Specifically, by analyzing genomic datasets using systems biology methods, we can systematically map the molecular pathways responsive to DEHP, identify hub genes mediating thyroid cancer occurrence, and ultimately bridge the gap between environmental exposure mechanisms and the discovery of therapeutic targets.

Materials and methods

Data acquisition for thyroid cancer

RNA-seq data, clinical data, and survival data in FPKM format for THCA were retrieved from the TCGA database (https://gdc-hub.s3.us-east-1.amazonaws.com/download/TCGA-THCA.star_fpkm.tsv.gz; Version 05-09-2024, n=580). Differential expression analysis was conducted using R 4.2.1 to generate volcano plots and heatmaps. Additionally, datasets GSE3467 (n=18), GSE3678 (n=14), GSE33630 (n=105), GSE53157 (n=27), and GSE60542 (n=92) were obtained from the GEO database. Differential expression analysis was performed using Xiantao Academic software using DESeq2[1.36.0] and edgeR [3.38.2] package. In the GEO merged dataset, DEGs were identified based on the criteria of adj.P.Val < 0.05 and |log2(FC)| > 1, resulting in the generation of volcano plots and heatmaps. However, in the TCGA dataset, |log2(FC)| > 0.2 was used, resulting in a smaller number of differentially expressed genes in the TCGA dataset. Therefore, after multiple attempts, this threshold was chosen.

Data acquisition for DEHP

The targeted molecular targets of DEHP were identified through an extensive search of the Comparative Toxicogenomics Database (CTD), Bioactive database of bioactive molecules with drug-like properties (ChEMBL), and Search Tool for Interactions of Chemicals (STITCH) databases. In the STITCH database, the default query is human, and molecular targets with medium confidence (> 0.4) are selected for filtering and screening. Select individuals from the CTD and ChEMBL database to screen for chemical-gene interactions. This target is a key site for chemical substances to exert biological effects. Following data integration from these sources, duplicate entries were removed to ensure data integrity.

Venn diagram

After intersecting the differential genes identified from TCGA, GEO, and DEHP datasets, we obtained the key pathogenic genes associated with DEHP-induced thyroid cancer and constructed a Venn diagram to illustrate the overlap. Screen out the genes that simultaneously appear in the three lists of DEHP target genes, TCGA DEGs and GEO DEGs. These genes have higher research value because they are not only related to DEHP, but also have expression differences between tumor tissues and normal tissues, and also show differential expression under other experimental conditions. It might be the key gene of DEHP that affects the biological behavior of cells.

Functional enrichment analysis

The Gene Ontology (GO) terms and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed using the clusterProfiler[4.4.4] package of Xiantao Academic, and significantly rich GO categories and KEGG pathways were identified. The statistical tests adopted in enrichment analysis are based on hypergeometric tests, which are typically used to evaluate the significance of GO and KEGG enrichment. The critical value of P for determining significance was set at 0.05. To correct the multiple tests, the Benjamini-Hochberg method was used to adjust the P value, thereby controlling the false detection rate (FDR). Only the GO classification and KEGG pathways with an adjusted P value less than 0.05 were considered significantly enriched.

Screening of hub genes

In the process of screening hub genes and developing prognostic models, we first conducted a univariate Cox regression analysis on six differentially expressed genes to evaluate the impact of each gene on disease survival. Subsequently, based on the results of the univariate analysis, a multivariate Cox regression analysis was further conducted to adjust for potential confounding factors (age, sex, tumor stage) and determine independent prognostic factors. Based on the results of multivariate Cox regression analysis, we developed a prognostic model to assess the disease risk of patients. The Risk Score of this model is calculated through the following formula:

Risk Score = (CYP1B1 expression level * coefficient) + (GABRB2 expression level * coefficient) + (TNFSF15 expression level * coefficient). And a risk factor correlation map was established.

Kaplan-Meier (KM) curves associated with risk factors were generated to further investigate patient survival. When dividing the high-risk group and the low-risk group, we used the median of the risk score as the critical value. In addition, a time-varying receiver operating characteristic (ROC) curve was constructed through the timeROC package to evaluate the accuracy of survival prediction, and the results were visualized using the ggplot2 package.

Check analysis

The ROC curve was used to evaluate the prognostic model for survival prediction in the GSE3467, GSE3678 and GSE33630 datasets.

Molecular docking

The three-dimensional structure of DEHP (PubChem CID: 8343) was retrieved from the PubChem database. The two-dimensional structure of DEHP was softened to a three-dimensional structure through Chem3D software. Thereafter, the protein’s 3D structure was acquired from the Protein Data Bank (PDB), and its species were all human, which were de-polymerized, de-small molecule ligands, hydrogenated and de-watered using Pymol software (http://www.pymol.org/). Autodock vina program (https://vina.scripps.edu/) was used for semi-flexible docking of a small-molecule ligand to a large-molecule receptor. Semi-flexible docking experiments were conducted on the target molecules using AutoDock 1.5.7 software to evaluate their binding affinity with receptor proteins. Each molecular docking experiment was run 20 times to ensure the reliability and statistical significance of the results. Each run uses a different initial conformation to explore the possible optimal binding mode between the receptor and the ligand. The semi-empirical free energy scoring function (AutoDock 4.0 scoring function) built into AutoDock was used. This function combines factors such as van der Waals forces, electrostatic interactions, and hydrophobic effects to evaluate the binding affinity between ligands and receptors. A binding energy less than -5 kcal/mol is generally regarded as indicating a good binding ability between the ligand and the receptor. The resultant docking configurations were visualized utilizing the PYMOL software.

Differential gene expression comparison

The key genes were compared and analyzed, and a box plot was generated.

Immunohistochemical sections of differential genes

The key genes were retrieved from the Human Protein Atlas (HPA) database, and the corresponding pathological sections were acquired.

Result

Acquisition of differential genes

A total of 68 differentially expressed genes were identified from the TCGA-THCA database, with 41 down-regulated genes and 27 up-regulated genes. while 716 differentially expressed genes were retrieved from the GEO database, 371 genes were downregulated and 345 genes were up-regulated. The volcano plots and heatmaps for both the TCGA and GEO datasets are presented in f1.

Intersection of target genes

Initially, a comprehensive search identified a total of 6,209 protein targets that were associated with DEHP. After intersecting the target molecules in the DEHP database with differential genes from the TCGA and GEO databases, six target genes were identified: CYP1B1, ABCC3, KRT19, CUX2, GABRB2, and TNFSF15 (f2).

Functional enrichment analysis

After performing GO and KEGG enrichment analysis on the six differentially expressed genes, it was found that GO Biological Process (BP) terms were primarily enriched in specific categories, such as regulation of postsynaptic membrane potential, synapse assembly and inorganic anion transport (f3). For GO Cellular Component (CC), the enrichment results are also presented, such as costamere, GABA-A receptor complex, apicolateral plasma membrane. In the Molecular Function (MF) category, the primary enrichment was observed in the pathways related to inorganic anion transmembrane transporter activity and ATPase-coupled inorganic anion transmembrane transporter activity. KEGG pathway analysis revealed a concentration in particular pathways, such as Antifolate resistance, Nicotine addiction and Tryptophan metabolism (f3). T1 provides a detailed description of the specific pathways and their respective proportions within each enrichment category.

Establishment of prognostic model

After performing COX-molecular regression analysis on the six differentially expressed genes (T2), it was revealed that CYP1B1, GABRB2, and TNFSF15 significantly influenced disease survival and risk stratification (f4). T3 presents. The establishment results of the multivariate COX regression model. Consequently, a prognostic model was developed. The time-dependent ROC curve analysis demonstrated that this model exhibited consistent predictive power at 3-year, 5-year, and 10-year intervals (AUC: 0.689, 0.679 and 0.685), indicating its potential clinical utility (f4). Additionally, survival curves generated from the TCGA database showed that patients in the high-risk group had a poorer prognosis compared to those in the low-risk group (f4).

Validation of target genes

The model was validated using five datasets (GSE3467, GSE3678 and GSE3363) from the GEO database. The areas of the ROC curves of a single dataset were divided into 100%, 91.4% and 96.4% (f5). The area under the ROC curve reached 86%, demonstrating the high reliability of the model (f5). Furthermore, by analyzing key genes, we observed that their expression levels were significantly higher in the cancer group compared to the normal group (f5) and p was significantly less than 0.05. Immunohistochemistry (IHC) images of these three key genes obtained from the HPA database provided additional evidence supporting their differential expression (f5).

Molecular docking

Molecular docking studies were conducted to investigate the interactions between DEHP and the proteins CYP1B1 (pdb_00003pm0), GABRB2 (pdb_00006x3t), and TNFSF15 (pdb_00002re9). T4 shows the details of the docking between DEHP and the corresponding target. f6 shows the molecular schematic diagram and the surface model respectively through the left and right panels. The black box in the left image focuses on the specific docking site, which is the active region where the ligand binds to the protein receptor. Here, the amino acid residues of the ligand and receptor interact through hydrogen bonds, and other means to form a fitting binding pocket. The 3D surface model on the right further presents the three-dimensional structure of the combined pocket, clearly demonstrating the complementarity between its shape and ligands, as well as how the surface charge distribution affects their combination, providing an intuitive basis for understanding the intermolecular interaction mechanism.

Discussion

This study investigates the network toxicological mechanisms underlying thyroid cancer induced by DEHP. CYP1B1, GABRB2, and TNFSF15 have been identified as significant target genes that can collectively predict the prognosis of thyroid cancer and possess high clinical value. Furthermore, these genes may play a crucial role in targeted therapy for thyroid cancer.

In human epidemiological studies (ref. 12, ref. 13) and in animal and in vitro experiments (ref. 14–ref. 17), phthalate plasticizers, particularly DEHP, have been shown to affect the hypothalamic-pituitary-thyroid (HPT) axis (ref. 18) and disrupt thyroid hormone homeostasis. Such interferences may potentially account for the recent high incidence of giant thyroid tumors (ref. 19). Studies have demonstrated a significant association between thyroid-related hormones and the risk of thyroid cancer (TC) (ref. 20). Thyroid hormones serve as mediators in tumor growth, proliferation, and progression (ref. 21, ref. 22). Our findings build on this foundation by linking DEHP exposure to specific molecular perturbations. Based on this, our research links DEHP exposure to specific molecular perturbations, using this to explain the specific molecular mechanisms and pathways by which DEHP mediates the occurrence of thyroid cancer.

For instance, several observational studies reporting negative correlations between DEHP metabolites and thyroid hormones (T3, T4) in general populations, pregnant women, and children (ref. 23) align with our KEGG enrichment in hormone metabolism pathways, where CYP1B1-known to metabolize xenobiotics—may modulate thyroid hormone bioavailability by interacting with T4-converting enzymes.​ CYP1B1-mediated xenobiotic metabolism, creating a feedback loop that amplifies hormonal disruption and genetic instability.​We indicates CYP1B1, a cytochrome P450 enzyme, may influence this process by metabolizing thyroid hormones, thereby altering their bioavailability and signaling potency. Additionally, thyroid hormones’ involvement in cell transformation, tumorigenesis, and metastasis (ref. 22) aligns with CYP1B1’s known role in mediating epithelial-mesenchymal transition (EMT) (ref. 24), a critical step in metastasis, creating a direct connection between hormonal signaling and our identified gene.​ Moreover, elevated free thyroxine (FT4) levels and reduced free triiodothyronine (FT3) levels associated with increased TC risk (ref. 25), and the proposed (FT4/FT3) ratio as a risk indicator (ref. 26), could be linked to CYP1B1’s function. As CYP1B1 is involved in xenobiotic metabolism, its dysregulation by DEHP may disrupt T4 to T3 conversion, contributing to the imbalanced FT4/FT3 ratio observed in malignant cases.​

Additionally, Ye et al. (ref. 27) found that DEHP-induced oxidative stress and ROS elevation, which activate the Ras/Akt/TRHr pathway and reduce TSH levels, provide a mechanistic link to our target genes. Since GABRB2 downregulation inhibits PI3K/AKT activation (ref. 28), DEHP-induced dysregulation of GABRB2 may synergize with T3 receptor mutations to amplify PI3K signaling, accelerating tumor development. The T3 receptors interaction with its promoter to regulate fibroblast growth factor expression in thyroid cells, and the finding that T3 receptor mutations enhance phosphatidylinositol 3-kinase signaling leading to thyroid tumors (ref. 29), directly intersect with our analysis of GABRB2. GABRB2, whose downregulation disinhibits PI3K/AKT signaling (ref. 28), may synergize with DEHP-activated Ras/Akt pathways to exacerbate TSH suppression, creating a pro-proliferative environment.

Histological changes from DEHP exposure-thyroid follicle hypertrophy, proliferation, and inflammatory infiltration (ref. 30)-are mirrored in our GO enrichment of cell cycle and inflammatory response terms, with TNFSF15 potentially driving this infiltration by recruiting pro-tumorigenic immune cells, as supported by its enrichment in TNF superfamily pathways. Given TNFSF15’s capacity to recruit pro-tumorigenic immune cells, it may contribute to the formation of an inflammatory microenvironment that enhances TSH-induced cell proliferation and the accumulation of mutations (ref. 31, ref. 32). Demircioglu et al. (ref. 33) reported that elevated preoperative TSH levels are associated with extrathyroidal extension and central lymph node metastasis, which aligns with the role of TNFSF15 in inflammatory signaling, as members of the TNF superfamily are frequently involved in mediating tissue invasion. The enhancement of immune function through TSH suppression therapy (ref. 34) may also involve TNFSF15, as its regulation could help mitigate inflammatory infiltration.

This study demonstrated that the prognostic model constructed based on target genes exhibits certain advantages, and integrated analysis can offer greater support for the treatment and management of thyroid cancer. This study has certain limitations. All data utilized in this paper were derived from databases and have not been validated through cellular or animal experiments. Future research will include in vitro validation using thyroid cell lines exposed to DEHP, and further investigation of the expression levels of CYP1B1, GABRB2 and TNFSF15 through molecular dynamics simulation and molecular interaction, as well as assessment of their functional impacts on cell proliferation, migration and apoptosis.

Conclusion

Through computational network toxicology analysis, this study identifies CYP1B1, GABRB2, and TNFSF15 as potential molecular targets mediating DEHP’s effects in thyroid cancer. These in silico findings provide novel insights into DEHP-associated thyroid carcinogenesis and suggest promising candidates for targeted therapy and prevention. Future experimental validation is essential to confirm the therapeutic relevance of these predicted targets.

References

1. AC Gore, VA Chappell, SE Fenton. EDC-2: the endocrine society’s second scientific statement on endocrine-disrupting chemicals.. Endocr Rev. (, 2015. [DOI | PubMed]
2. ATSDR fact sheets on hazardous substances. Agency for toxic substances and disease registry.. Public Health Rep. (, 2001. [PubMed]
3. J Högberg, A Hanberg, M Berglund. Phthalate diesters and their metabolites in human breast milk, blood or serum, and urine as biomarkers of exposure in vulnerable populations.. Environ Health Perspect. (, 2008. [DOI | PubMed]
4. V Marotta, G Russo, C Gambardella. Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules.. Chemosphere. (, 2019. [DOI | PubMed]
5. X Zhang, N Guo, H Jin, R Liu, Z Zhang, C Cheng. Bisphenol A drives di(2-ethylhexyl) phthalate promoting thyroid tumorigenesis via regulating HDAC6/PTEN and c-MYC signaling.. J Hazard Mater. (, 2022. [DOI | PubMed]
6. M Boas, U Feldt-Rasmussen, KM Main. Thyroid effects of endocrine disrupting chemicals.. Mol Cell Endocrinol. (, 2012. [DOI | PubMed]
7. MJ Kim, S Moon, BC Oh. Association between diethylhexyl phthalate exposure and thyroid function: A meta-analysis.. Thyroid. (, 2019. [DOI | PubMed]
8. X Zhang, Y Zhao, C Cheng. Combined effects of di (2-ethylhexyl) phthalate and bisphenol A on thyroid hormone homeostasis in adolescent female rats.. Environ Sci pollut Res Int. (, 2020. [DOI | PubMed]
9. JK Kim, J Zhang, S Hwang. Transcriptome-metabolome-wide association study (TMWAS) in rats revealed a potential carcinogenic effect of DEHP in thyroid associated with eicosanoids.. Environ Res. (, 2022. [DOI | PubMed]
10. H Miao, X Liu, J Li, L Zhang, Y Zhao, S Liu. Associations of urinary phthalate metabolites with risk of papillary thyroid cancer.. Chemosphere. (, 2020. [DOI | PubMed]
11. L Boucai, M Zafereo, ME Cabanillas. Thyroid cancer: A review.. Jama. (, 2024. [DOI | PubMed]
12. A Derakhshan, H Shu, MAC Broeren, CH Lindh, RP Peeters, A Kortenkamp. Association of phthalate exposure with thyroid function during pregnancy.. Environ Int. (, 2021. [DOI | PubMed]
13. HB Huang, CJ Chuang, PH Su, CW Sun, CJ Wang, MT Wu. Prenatal and childhood exposure to phthalate diesters and thyroid function in a 9-year follow-up birth cohort study: Taiwan maternal and infant cohort study.. Epidemiology. (, 2017. [DOI | PubMed]
14. H Wu, W Zhang, Y Zhang, Z Kang, X Miao, X Na. Novel insights into di−(2−ethylhexyl)phthalate activation: Implications for the hypothalamus−pituitary−thyroid axis.. Mol Med Rep. (, 2021. [DOI | PubMed]
15. N Kambia, I Séverin, A Farce, L Dahbi, T Dine, E Moreau. Comparative effects of di-(2-ethylhexyl)phthalate and di-(2-ethylhexyl)terephthalate metabolites on thyroid receptors: in vitro and in silico studies.. Metabolites. (, 2021. [DOI | PubMed]
16. D Sun, L Zhou, S Wang. Effect of Di-(2-ethylhexyl) phthalate on the hypothalamus-pituitary-thyroid axis in adolescent rat.. Endocr J. (, 2022. [DOI | PubMed]
17. X Zhang, W Qi, Q Xu. Di(2-ethylhexyl) phthalate (DEHP) and thyroid: biological mechanisms of interference and possible clinical implications.. Environ Sci pollut Res Int. (, 2022. [DOI | PubMed]
18. S Benjamin, E Masai, N Kamimura, K Takahashi, RC Anderson, PA Faisal. Phthalates impact human health: Epidemiological evidences and plausible mechanism of action.. J Hazard Mater. (, 2017. [DOI | PubMed]
19. D Vrinceanu, M Dumitru, A Marinescu, C Serboiu, G Musat, M Radulescu. Management of giant thyroid tumors in patients with multiple comorbidities in a tertiary head and neck surgery center.. Biomedicines. (, 2024. [DOI | PubMed]
20. Z Wang, Y Lin, Y Jiang. The associations between thyroid-related hormones and the risk of thyroid cancer: An overall and dose-response meta-analysis.. Front Endocrinol (Lausanne). (, 2022. [DOI | PubMed]
21. P Petranović Ovčariček, FA Verburg, M Hoffmann. Higher thyroid hormone levels and cancer.. Eur J Nucl Med Mol Imaging. (, 2021. [DOI | PubMed]
22. M Pinto, P Soares, D Ribatti. Thyroid hormone as a regulator of tumor induced angiogenesis.. Cancer Lett. (, 2011. [DOI | PubMed]
23. A Rodríguez-Carrillo, E Salamanca-Fernández, E Den Hond. Association of exposure to perfluoroalkyl substances (PFAS) and phthalates with thyroid hormones in adolescents from HBM4EU aligned studies.. Environ Res. (, 2023. [DOI | PubMed]
24. S Moretti, N Nucci, E Menicali, S Morelli, V Bini, R Colella. The aryl hydrocarbon receptor is expressed in thyroid carcinoma and appears to mediate epithelial-mesenchymal-transition.. Cancers (Basel). (, 2020. [DOI | PubMed]
25. M Ambroziak, J Pachucki, E Stachlewska-Nasfeter. Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as titf1/nkx2–1 and pax-8 transcription factor genes in papillary thyroid cancer.. Thyroid. (, 2005. [DOI | PubMed]
26. M Sasson, E Kay-Rivest, R Shoukrun. The T4/T3 quotient as a risk factor for differentiated thyroid cancer: a case control study.. J Otolaryngol Head Neck Surg. (, 2017. [DOI | PubMed]
27. H Ye, M Ha, M Yang, P Yue, Z Xie, C Liu. Di2-ethylhexyl phthalate disrupts thyroid hormone homeostasis through activating the Ras/Akt/TRHr pathway and inducing hepatic enzymes.. Sci Rep. (, 2017. [DOI | PubMed]
28. C Xiu, X Deng, D Deng. miR-144-3p targets GABRB2 to suppress thyroid cancer progression in vitro .. Cell Biochem Biophys. (, 2024. [DOI | PubMed]
29. F Furuya, H Ying, L Zhao. Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription.. Steroids. (, 2007. [DOI | PubMed]
30. H Wu, K Ma, X Na. Rosmarinic acid alleviates di-2-ethylhexyl phthalate (DEHP) -induced thyroid dysfunction via multiple inflammasomes activation.. J Toxicol Sci. (, 2020. [DOI | PubMed]
31. A Amado, B Castro, AP Torre. Serum TSH as a predictor of Malignancy in indeterminate thyroid nodules.. Ann R Coll Surg Engl. (, 2022. [DOI | PubMed]
32. B Xu, SY Gu, NM Zhou. Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: A meta-analysis.. Open Life Sci. (, 2023. [DOI | PubMed]
33. ZG Demircioglu, MK Demircioglu, N Aygun. Relationship between thyroid-stimulating hormone level and aggressive pathological features of papillary thyroid cancer.. Sisli Etfal Hastan Tip Bul. (, 2022. [DOI | PubMed]
34. JJ Liang, WJ Feng, R Li. Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer.. World J Clin cases. (, 2023. [DOI | PubMed]